NIH may give ElevateBio exclusive CAR T license

NIH's National Cancer Institute is considering granting ElevateBio LLC (Cambridge, Mass.) an exclusive license to develop an undisclosed CAR T therapy targeting FMS-like tyrosine kinase 3 (FLT3; CD135).

In a Federal Registry notice, NIH said it is accepting comments and/or applications for a license for FLT3-specific CAR Ts until Dec. 4. The notice lists two patent applications filed by NCI for development of a FLT3 CAR-based immunotherapy and for a CAR vector comprising an anti-FLT3 antibody, known as NC7, and an intracellular signaling domain...